ReviewInternational journal of clinical and experimental medicine2015

Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.

Liangqing Ge et al.PubMed ↗Full text ↗

No numbers read from the abstract.